A researcher who turns the body’s own cells into better medical treatments is joining the University of Waterloo as one of its inaugural Eddie Goldenberg Research Chairs.
Dr. Ruibing Wang, currently a professor of supramolecular pharmaceutics and biomaterials at the University of Macau, will join the Faculty of Engineering in April 2027 as Eddie Goldenberg Research Chair in Supramolecular Biomaterials. He is one of three chairs appointed to Waterloo through the Government of Canada program, alongside Dr. Talia Bettcher and Dr. James Wolffsohn.
Rather than changing a cell’s genetic code, Wang’s team uses reversible host-guest molecules to attach nanomedicine to immune cells, platelets and red blood cells, giving them new abilities to fight disease. The goal is to make advanced treatments, such as some cancer therapies, faster to develop, more affordable and accessible to more patients, while building a stronger Canadian manufacturing base for biological treatments. Wang has published more than 300 peer-reviewed articles and has been named to Stanford University’s list of the world’s top two per cent of scientists every year since 2020. At Waterloo, he plans to draw on the University’s creator-owned intellectual property policy, startup ecosystem and health partnerships to move discoveries from the lab to real-world use while training the next generation of scientists and entrepreneurs.
Read Turning the body’s own cells into better medicine for a Q&A with Wang, and learn more about Waterloo’s inaugural Eddie Goldenberg Research Chairs of Canada.
